Royal Bank of Canada
BXRX

Royal Bank of Canada’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Royal Bank of Canada’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15
Closed – – 8215
2022
Q3 		$0 Buy
+15
New +$349 ﹤0.01% 8273
2021
Q2 		– Hold
0
– -$1K – 7887
2021
Q1 		– Sell
-6
Closed -$12K – 7361
2020
Q4 		$8K Hold
6
– – ﹤0.01% 6503
2020
Q3 		$23K Hold
6
– – ﹤0.01% 5652
2020
Q2 		$35K Sell
6
-2
-25% -$9.6K ﹤0.01% 5372
2020
Q1 		$26K Buy
8
+2
+33% +$18.9K ﹤0.01% 5442
2019
Q4 		$58K Buy
+6
New +$51.2K ﹤0.01% 5387

Other funds holding BXRX

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SN
Sittner & Nelson Eugene, Oregon $318M AUM 31.11% 1-Year Est. Return

Royal Bank of Canada's BXRX Position: Q4 2022 in Review

Royal Bank of Canada sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2022, closing a stake of 15 shares.

Royal Bank of Canada first reported a position in BXRX in Q4 2019 and held it in 6 quarters. The position peaked at $58K in Q4 2019. 10 funds tracked by Wall St. Rank hold BXRX as of Q4 2022.

  • Royal Bank of Canada reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Royal Bank of Canada sold 15 Baudax Bio, Inc. Common Stock shares in Q4 2022.
  • Royal Bank of Canada first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 6 quarters.
  • Royal Bank of Canada's Baudax Bio, Inc. Common Stock position peaked at $58K in Q4 2019.
  • 10 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2022.

Based on Royal Bank of Canada's 13F filing for Q4 2022, filed 14 Feb 2023.